{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:14:33Z","timestamp":1795054473217,"version":"4.10.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ygyno.2021.03.016","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T16:22:58Z","timestamp":1616689378000},"page":"687-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer"],"prefix":"10.1016","volume":"161","author":[{"given":"Olga T.","family":"Filippova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Shahrokni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.03.016_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovaraina, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery of neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.016_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.016_bb0015","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/IGC.0000000000000241","article-title":"O Mogensen, R dePont Christense, and P tine Jensen. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?","volume":"24","author":"Markauskas","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2021.03.016_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039415","article-title":"Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer","volume":"7","author":"Rafii","year":"2012","journal-title":"PLoS One"},{"issue":"9990","key":"10.1016\/j.ygyno.2021.03.016_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ygyno.2021.03.016_bb0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"CG trope, F Amant, GB Kristensen, T Ehlen, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"15, supplement","key":"10.1016\/j.ygyno.2021.03.016_bb0035","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/JCO.2018.36.15_suppl.5516","article-title":"Survival analyses form a randomized trial of primary debulking surgery versus neoaduvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)","volume":"36","author":"Fagotti","year":"2018","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.016_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.016_bb0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.03.016_bb0050","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/IGC.0000000000000946","article-title":"A comparison of survival outcomes in advanced serous ovarian cancer patients treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"27","author":"May","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.03.016_bb0055","first-page":"5500","article-title":"Comaprison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in pahse III randomized trial: JCOG0602","volume":"36","author":"Onda","year":"2018","journal-title":"JSO"},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.016_bb0060","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.03.016_bb0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","article-title":"A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer","volume":"134","author":"Suidan","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.016_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2019.04.683","article-title":"Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center","volume":"154","author":"Filippova","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.016_bb0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2011.06.031","article-title":"Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovaria cancer: a delicate balance requiring individualization","volume":"123","author":"Langstraat","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.03.016_bb0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jgo.2016.07.008","article-title":"Ovarian cancer in the older woman","volume":"7","author":"Tew","year":"2016","journal-title":"J Geriatric Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2021.03.016_bb0085","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.2014.55.0962","article-title":"Surgical consideration in older adults with cancer","volume":"32","author":"Korc-Grodzicki","year":"2014","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.ygyno.2021.03.016_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3545","article-title":"Development and evaluation of a new frailty index for older surgical patients with cancer","volume":"2","author":"Shahrokni","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2021.03.016_bb0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jgo.2018.08.010","article-title":"Predicting chemotherapy toxicity in older adults: comparing the predictive value of the CARG toxicity score with oncologists\u2019 estimates of toxicity based on clinical judgement","volume":"10","author":"Moth","year":"2019","journal-title":"J. Geriatric Oncol."},{"key":"10.1016\/j.ygyno.2021.03.016_bb0100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jgo.2019.12.016","article-title":"Comapring the performance of the CARG and the CRASH score for predicting toxicity in older patients with cancer","volume":"11","author":"Ortland","year":"2020","journal-title":"J. Geriatric Oncol."},{"key":"10.1016\/j.ygyno.2021.03.016_bb0105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2018.06.020","article-title":"Neoadjuvant chemotherapy in elderly women with ovarian cancer: rate of use and effectiveness","volume":"150","author":"Meyer","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.016_bb0110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2015.01.532","article-title":"Frailty index predicts severe complications in gynecologic oncology patients","volume":"137","author":"Uppal","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.016_bb0115","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjsurg.2013.03.012","article-title":"Simple frailty score predicts postoperative complications across surgical specialties","volume":"206","author":"Robinson","year":"2013","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ygyno.2021.03.016_bb0120","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","article-title":"Comperehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study","volume":"16","author":"Freyer","year":"2005","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.016_bb0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.6004\/jnccn.2017.0018","article-title":"A tin, RJ Downey, V strong, S Mahmoudzadeh, et al. electronic rapid fitness assessment: a novel tool for preoperative evaluation of the geriatric oncology patients","volume":"15","author":"Shahrokni","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2021.03.016_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2019.04.683","article-title":"Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center","volume":"154","author":"Filippova","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2021.03.016_bb0135","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"JCO"},{"issue":"S1","key":"10.1016\/j.ygyno.2021.03.016_bb0140","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2105\/AJPH.2009.162982","article-title":"Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change","volume":"100","author":"Herrera","year":"2010","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.ygyno.2021.03.016_bb0145","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/ijgc-2019-000597","article-title":"Role and impact of multimodal prehabilitation for gynecologic oncology patient in an enhanced recovery after surgery (ERAS) program","volume":"29","author":"Miralpeix","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.03.016_bb0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00404-019-05321-7","article-title":"Prehabilitation programs and ERAS protocols in gynecologic incology: a comprehensive review","volume":"301","author":"Schneider","year":"2020","journal-title":"Arch. Gynecol. Obstet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:48:21Z","timestamp":1715820501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821002523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0090825821002523"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}